










Heron Therapeutics Appoints Kimberly J. Manhard As Executive Vice President Of Drug Development - TheStreet




































































 

 




















Action Alerts PLUS

Access AAPJim Cramer's Best Stocks for 2017Charitable Trust PortfolioMost Recent Trade Alert25 Investing Rules10 Trading Commandments

Real Money

Access RM25 Rules of InvestingJim Cramer's Best Stocks for 201710 CommandmentsStressed Out StocksCramer's Blog

Cramer
Mad Money
ETFs
Futures
Markets
Much More

BanksBiotechRetailTechPersonal FinanceRetirementFinancial Advisor CenterHow to SpendOptionsFixed IncomeVideo










Privacy Policy|Terms of Use© 1996- TheStreet Inc. All rights reserved
















                                DJIA
                            







                                NASDAQ
                            







                                S&P 500
                            






Market Data updated






Sign In




Your Membership(s)








Your Account





Account Preferences


Alerts


Newsletters







Subscribe





Logout



Subscribe

Access insights and guidance from our Wall Street pros. Find the product that's right for you.
Action Alerts PLUS
Action Alerts OPTIONS
Daily Swing Trade
Income Seeker
Quant Ratings
Real Money
Real Money Pro
Stocks Under $10
Top Stocks
Trifecta Stocks
Real Money Pro Portfolio
Chairman's Club
Compare All 
Chatter on the Street













































 








































Heron Therapeutics Appoints Kimberly J. Manhard As Executive Vice President Of Drug Development






Business Wire




Jan 28, 2016 8:00 AM EST













 




























































  Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company focused on improving the lives of patients by developing best-in-class medicines that address major unmet medical needs, today announced the appointment of Kimberly J. Manhard as Executive Vice President of Drug Development. Ms. Manhard joins the Company today and will report to Barry D. Quart, Pharm.D., Chief Executive Officer of Heron.  "Kimberly has played an important role at Heron since joining our Board of Directors in January 2014, so we are delighted that she will be joining the Company as a permanent member of our leadership team," commented Dr. Quart. "Kimberly brings to her role at Heron over 25 years of drug development, regulatory affairs and pharmaceutical operations experience, which will be invaluable to the Company as we move forward with the development of our exciting pipeline of product candidates targeting cancer or pain."  Since 2008, Ms. Manhard has served as the Senior Vice President of Regulatory Affairs and Development Operations at Ardea Biosciences, Inc., a wholly-owned subsidiary of AstraZeneca PLC. In her role at Ardea, Ms. Manhard was instrumental in the development and December 2015 regulatory approval of Zurampic ® (lesinurad), by the U.S. Food and Drug Administration (FDA) for the treatment of hyperuricemia associated with gout. Ms. Manhard joined Ardea in 2006, overseeing general corporate operations. Ardea Biosciences, Inc. was acquired by AstraZeneca PLC for $1.26 billion in June 2012. Since its sale, Ms. Manhard took on the additional roles of Ardea's Corporate Compliance Officer and as a director of Ardea Biosciences Limited. Prior to her tenure at Ardea, Ms. Manhard was President of her own consultancy firm, Vice President of Regulatory Affairs for Exelixis, Inc., and held multiple regulatory positions at Agouron Pharmaceuticals, Inc., a Pfizer Inc. company, supporting the development and commercialization of anticancer and antiviral products, including Viracept ® (nelfinavir). She was also previously with Bristol Myers Squibb Company in regulatory affairs, responsible for oncology compounds, including Taxol ® (paclitaxel) and infectious disease compounds, including Videx ® (didanosine) and Zerit ® (stavudine).  About Heron Therapeutics, Inc.  Heron Therapeutics, Inc. is a biotechnology company focused on improving the lives of patients by developing best-in-class medicines that address major unmet medical needs. Heron is developing novel, patient-focused solutions that apply its innovative science and technologies to already-approved pharmacological agents for patients suffering from cancer or pain. Heron's goal is to build on therapeutics with well-known pharmacology by improving their tolerability and efficacy as well as broadening their potential field of use. For more information, visit www.herontx.com.  Forward Looking Statements  This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, those associated with: whether the U.S. Food and Drug Administration (FDA) completes its review within the anticipated time period, whether the FDA approves the SUSTOL NDA as submitted or supports as broad of a labeled indication for SUSTOL as requested, the potential market opportunity for SUSTOL and expected timing of the commercial launch, the progress in the research and development of HTX-019, HTX-011 and our other programs, including the timing of preclinical, clinical, and manufacturing activities, safety and efficacy results from our studies that may not justify the pursuit of further development of our product candidates, acceptance of SUSTOL and new products generally, our financial position and our ability to raise additional capital to fund operations, if necessary, or to pursue additional business opportunities, strategic business alliances we may pursue or the potential acquisition of products or technologies, and our ability to grow our organization to sustain the commercial launch for SUSTOL, and other risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.  



 








 










































If you liked this article you might like













Here's Why Investors Should Steer Clear of Opioids
Backed by the government, initiatives to develop and popularize non-opioid painkillers can make investors high on profits.



Chiradeep BasuMallick

Sep 6, 2016 12:37 PM EDT
























Biotech Stock Mailbag: Heron, Acadia, Exact Sciences, Sarepta
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.



Adam Feuerstein

Aug 12, 2016 7:01 AM EDT
























Biotech Stock Mailbag: Heron, Exelixis
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.



Adam Feuerstein

Jul 8, 2016 6:58 AM EDT
























Heron and the Never-Ending FDA Drug Review
Heron Therapeutics won't explain why the FDA is taking so long to render an approval decision for Sustol, the company's lead supportive cancer care drug.



Adam Feuerstein

May 18, 2016 12:22 PM EDT








































 











Trending


Boeing Could Soar Another 100,000 Feet and Stay the Hottest Dow Jones Industrial Average Performer


Sears Just Surrendered to Amazon With Kenmore Deal


Meeting $12 Billion Cash Target Proves Tougher Than GE Expected


15 Foods to Avoid if You Have High Cholesterol


BMW Has One of the 10 Hot New Luxury Cars Priced Over $100,000 That You Could Buy Today











Advertising Partners



 






 






 






 


























 

























 































 


©1996-2017 TheStreet, Inc. All rights reserved.Action Alerts PLUS is a registered trademark of TheStreet, Inc.




Compare Brokers



 







 







 







 







 







 












 



Heron Therapeutics Appoints Kimberly J. Manhard as Executive Vice President of Drug Development | Business Wire
























































      Heron Therapeutics Appoints Kimberly J. Manhard as Executive Vice 
      President of Drug Development
    





January 28, 2016 08:00 AM Eastern Standard Time



REDWOOD CITY, Calif.--(BUSINESS WIRE)--Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company focused 
      on improving the lives of patients by developing best-in-class medicines 
      that address major unmet medical needs, today announced the appointment 
      of Kimberly J. Manhard as Executive Vice President of Drug Development. 
      Ms. Manhard joins the Company today and will report to Barry D. Quart, 
      Pharm.D., Chief Executive Officer of Heron.
    


      “Kimberly has played an important role at Heron since joining our Board 
      of Directors in January 2014, so we are delighted that she will be 
      joining the Company as a permanent member of our leadership team,” 
      commented Dr. Quart. “Kimberly brings to her role at Heron over 25 years 
      of drug development, regulatory affairs and pharmaceutical operations 
      experience, which will be invaluable to the Company as we move forward 
      with the development of our exciting pipeline of product candidates 
      targeting cancer or pain.”
    

      Since 2008, Ms. Manhard has served as the Senior Vice President of 
      Regulatory Affairs and Development Operations at Ardea Biosciences, 
      Inc., a wholly-owned subsidiary of AstraZeneca PLC. In her role at 
      Ardea, Ms. Manhard was instrumental in the development and December 2015 
      regulatory approval of Zurampic® (lesinurad), by the U.S. 
      Food and Drug Administration (FDA) for the treatment of hyperuricemia 
      associated with gout. Ms. Manhard joined Ardea in 2006, overseeing 
      general corporate operations. Ardea Biosciences, Inc. was acquired by 
      AstraZeneca PLC for $1.26 billion in June 2012. Since its sale, Ms. 
      Manhard took on the additional roles of Ardea's Corporate Compliance 
      Officer and as a director of Ardea Biosciences Limited. Prior to her 
      tenure at Ardea, Ms. Manhard was President of her own consultancy firm, 
      Vice President of Regulatory Affairs for Exelixis, Inc., and held 
      multiple regulatory positions at Agouron Pharmaceuticals, Inc., a Pfizer 
      Inc. company, supporting the development and commercialization of 
      anticancer and antiviral products, including Viracept® 
      (nelfinavir). She was also previously with Bristol Myers Squibb Company 
      in regulatory affairs, responsible for oncology compounds, including 
      Taxol® (paclitaxel) and infectious disease compounds, 
      including Videx® (didanosine) and Zerit® 
      (stavudine).
    

About Heron Therapeutics, Inc.


      Heron Therapeutics, Inc. is a biotechnology company focused on improving 
      the lives of patients by developing best-in-class medicines that address 
      major unmet medical needs. Heron is developing novel, patient-focused 
      solutions that apply its innovative science and technologies to 
      already-approved pharmacological agents for patients suffering from 
      cancer or pain. Heron’s goal is to build on therapeutics with well-known 
      pharmacology by improving their tolerability and efficacy as well as 
      broadening their potential field of use. For more information, visit www.herontx.com.
    

Forward Looking Statements


      This news release contains "forward-looking statements" as defined by 
      the Private Securities Litigation Reform Act of 1995. Heron cautions 
      readers that forward-looking statements are based on management’s 
      expectations and assumptions as of the date of this news release and are 
      subject to certain risks and uncertainties that could cause actual 
      results to differ materially. These risks and uncertainties include, but 
      are not limited to, those associated with: whether the U.S. Food and 
      Drug Administration (FDA) completes its review within the anticipated 
      time period, whether the FDA approves the SUSTOL NDA as submitted or 
      supports as broad of a labeled indication for SUSTOL as requested, the 
      potential market opportunity for SUSTOL and expected timing of the 
      commercial launch, the progress in the research and development of 
      HTX-019, HTX-011 and our other programs, including the timing of 
      preclinical, clinical, and manufacturing activities, safety and efficacy 
      results from our studies that may not justify the pursuit of further 
      development of our product candidates, acceptance of SUSTOL and new 
      products generally, our financial position and our ability to raise 
      additional capital to fund operations, if necessary, or to pursue 
      additional business opportunities, strategic business alliances we may 
      pursue or the potential acquisition of products or technologies, and our 
      ability to grow our organization to sustain the commercial launch for 
      SUSTOL, and other risks and uncertainties identified in the Company's 
      filings with the Securities and Exchange Commission. Forward-looking 
      statements reflect our analysis only on their stated date, and Heron 
      takes no obligation to update or revise these statements except as may 
      be required by law.
    




Contacts

Investor Relations Contact:Jennifer Capuzelo, 858-703-6063Associate 
      Director, Investor Relationsjcapuzelo@herontx.comCorporate 
      Contact:Barry D. Quart, Pharm D., 650-366-2626Chief 
      Executive Officer
    



















Contacts

Investor Relations Contact:Jennifer Capuzelo, 858-703-6063Associate 
      Director, Investor Relationsjcapuzelo@herontx.comCorporate 
      Contact:Barry D. Quart, Pharm D., 650-366-2626Chief 
      Executive Officer
    








 
 

 






Search




Advanced News Search

Advanced News Search













Log In
Sign Up

















Heron Therapeutics Appoints Kimberly J. Manhard as Executive Vice President of Drug Development





























































Heron Therapeutics Appoints Kimberly J. Manhard as Executive Vice President of Drug Development
























Tweet




















January 28, 2016 - 05:01 AM PST


REDWOOD CITY, Calif.



(Business Wire)  
      Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company focused 
      on improving the lives of patients by developing best-in-class medicines 
      that address major unmet medical needs, today announced the appointment 
      of Kimberly J. Manhard as Executive Vice President of Drug Development. 
      Ms. Manhard joins the Company today and will report to Barry D. Quart, 
      Pharm.D., Chief Executive Officer of Heron.
    

      “Kimberly has played an important role at Heron since joining our Board 
      of Directors in January 2014, so we are delighted that she will be 
      joining the Company as a permanent member of our leadership team,” 
      commented Dr. Quart. “Kimberly brings to her role at Heron over 25 years 
      of drug development, regulatory affairs and pharmaceutical operations 
      experience, which will be invaluable to the Company as we move forward 
      with the development of our exciting pipeline of product candidates 
      targeting cancer or pain.”
    

      Since 2008, Ms. Manhard has served as the Senior Vice President of 
      Regulatory Affairs and Development Operations at Ardea Biosciences, 
      Inc., a wholly-owned subsidiary of AstraZeneca PLC. In her role at 
      Ardea, Ms. Manhard was instrumental in the development and December 2015 
      regulatory approval of Zurampic® (lesinurad), by the U.S. 
      Food and Drug Administration (FDA) for the treatment of hyperuricemia 
      associated with gout. Ms. Manhard joined Ardea in 2006, overseeing 
      general corporate operations. Ardea Biosciences, Inc. was acquired by 
      AstraZeneca PLC for $1.26 billion in June 2012. Since its sale, Ms. 
      Manhard took on the additional roles of Ardea's Corporate Compliance 
      Officer and as a director of Ardea Biosciences Limited. Prior to her 
      tenure at Ardea, Ms. Manhard was President of her own consultancy firm, 
      Vice President of Regulatory Affairs for Exelixis, Inc., and held 
      multiple regulatory positions at Agouron Pharmaceuticals, Inc., a Pfizer 
      Inc. company, supporting the development and commercialization of 
      anticancer and antiviral products, including Viracept® 
      (nelfinavir). She was also previously with Bristol Myers Squibb Company 
      in regulatory affairs, responsible for oncology compounds, including 
      Taxol® (paclitaxel) and infectious disease compounds, 
      including Videx® (didanosine) and Zerit® 
      (stavudine).
    

About Heron Therapeutics, Inc.


      Heron Therapeutics, Inc. is a biotechnology company focused on improving 
      the lives of patients by developing best-in-class medicines that address 
      major unmet medical needs. Heron is developing novel, patient-focused 
      solutions that apply its innovative science and technologies to 
      already-approved pharmacological agents for patients suffering from 
      cancer or pain. Heron’s goal is to build on therapeutics with well-known 
      pharmacology by improving their tolerability and efficacy as well as 
      broadening their potential field of use. For more information, visit www.herontx.com.
    

Forward Looking Statements


      This news release contains "forward-looking statements" as defined by 
      the Private Securities Litigation Reform Act of 1995. Heron cautions 
      readers that forward-looking statements are based on management’s 
      expectations and assumptions as of the date of this news release and are 
      subject to certain risks and uncertainties that could cause actual 
      results to differ materially. These risks and uncertainties include, but 
      are not limited to, those associated with: whether the U.S. Food and 
      Drug Administration (FDA) completes its review within the anticipated 
      time period, whether the FDA approves the SUSTOL NDA as submitted or 
      supports as broad of a labeled indication for SUSTOL as requested, the 
      potential market opportunity for SUSTOL and expected timing of the 
      commercial launch, the progress in the research and development of 
      HTX-019, HTX-011 and our other programs, including the timing of 
      preclinical, clinical, and manufacturing activities, safety and efficacy 
      results from our studies that may not justify the pursuit of further 
      development of our product candidates, acceptance of SUSTOL and new 
      products generally, our financial position and our ability to raise 
      additional capital to fund operations, if necessary, or to pursue 
      additional business opportunities, strategic business alliances we may 
      pursue or the potential acquisition of products or technologies, and our 
      ability to grow our organization to sustain the commercial launch for 
      SUSTOL, and other risks and uncertainties identified in the Company's 
      filings with the Securities and Exchange Commission. Forward-looking 
      statements reflect our analysis only on their stated date, and Heron 
      takes no obligation to update or revise these statements except as may 
      be required by law.
    


View source version on businesswire.com: http://www.businesswire.com/news/home/20160128005330/en/ 

Filed In:
Health, 
Medical, 
Cancer, 
Pharmaceuticals, 
Biotechnology


help us maintain quality content — report this story






Feed


Email


PDF


Print








Contact




      Investor Relations Contact:Jennifer Capuzelo, 858-703-6063Associate 
      Director, Investor Relationsjcapuzelo@herontx.comCorporate 
      Contact:Barry D. Quart, Pharm D., 650-366-2626Chief 
      Executive Officer
    







More


Read more stories from A.P. Pharma, Inc.






 
























Home | About | dlvr.it Social | Browser Extension | Contact | API | Help | TOS

add your story  






 




Kimberly J. Manhard: Executive Profile & Biography - Bloomberg









































  





















































































July 21, 2017 11:05 AM ET
Biotechnology

Company Overview of Heron Therapeutics, Inc.



SnapshotPeople 




OverviewBoard MembersCommittees



Executive Profile
Kimberly J. Manhard  Executive Vice President of Drug Development, Heron Therapeutics, Inc.AgeTotal Calculated CompensationThis person is connected to 0 Board Members in 0 different organizations across 4 different industries.57$6,346,694As of Fiscal Year 2016
Background

		Ms. Kimberly J. Manhard has been an Executive Vice President of Drug Development at Heron Therapeutics, Inc. since January 28, 2016. Ms. Manhard has been a Senior Vice President of Regulatory Affairs and Development Operations at Ardea Biosciences, Inc., since December 21, 2006. and served as its Senior Vice President of Regulatory Affairs and Operations. She has been President of her own consultancy since 2003, specializing in the development of small molecules intended ... for antiviral, oncology, central nervous system and gastrointestinal indications and is responsible for filing five initial US INDs and multiple clinical trial applications in the European Union and Canada. She served as Vice President of Regulatory Affairs of Napo Pharmaceuticals, Inc. She served as Senior Vice President of Regulatory Affairs & Operations of Intrabiotics Pharmaceuticals Inc. since December 22, 2006. She joined Napo Pharmaceuticals, Inc. from Exelixis, Inc., where she served as Vice President of Regulatory Affairs. She joined Agouron in 1996 as Director of Regulatory Affairs and was responsible for anticancer and antiviral products, including nelfinavir. Prior to that, she was with Agouron Pharmaceuticals, Inc. where she was responsible for global regulatory functions. She has more than 20 years of experience in the pharmaceutical industry and has participated in more than 15 IND submissions and at least six drug approvals for both small molecule and biological drugs primarily in the areas of antivirals and cancer. Her prior pharmaceuticals company experience includes Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb and Eli Lilly & Co. She served as a Director of Heron Therapeutics, Inc. since January 13, 2014 until January 28, 2016. She studied B.S. Degree in Zoology and B.A. in French from the University of Florida, Gainesville.Read Full Background




Corporate Headquarters
4242 Campus Point CourtSan Diego, California 92121United StatesPhone: 858-251-4400Fax: --
Board Members Memberships
				There is no Board Members Memberships data available.
				Education
BA University of FloridaBS University of Florida
Other Affiliations
Exelixis, Inc.Intrabiotics Pharmaceuticals Inc.University of FloridaNapo Pharmaceuticals, Inc.Ardea Biosciences, Inc.


Annual Compensation
Salary$401,077Total Annual Compensation$401,077
Stocks Options
All Other Compensation$7,950Exercisable Options$23,126Exercisable Options Value$88,558Unexercisable Options$420,000Unexercisable Options Value$12,000Total Value of Options$100,557Total Number of Options$443,126
Total Compensation
Total Annual Cash Compensation$544,736Total Short Term Compensation$401,077Other Long Term Compensation$7,950Total Calculated Compensation$6,346,694




Request Profile Update
















 












The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking 
	here.




Stock Quotes


Market data is delayed at least 15 minutes.







Company Lookup



COMPETITOR COMPENSATIONThere is no Competitor Compensation data available.










Sponsored Financial Commentaries

Sponsored Links






Browse Companies
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
 | 
0
1
2
3
4
5
6
7
8
9






Request Profile Update

						Only a company representative may request an update for the company profile. Documentation will be required.
					  
To contact Heron Therapeutics, Inc., please visit .  Company data is provided by S&P Global Market Intelligence.  Please use this form to report any data issues.
					  


Information Missing - Please enter your information in the following field(s): 




Company Name

Your Name*

Your E-Mail Address*

Your Phone Number*

Type of Data*


Overview
Executives
Key developments
Similar companies
Transactions


Update Needed*

All data changes require verification from public sources.  Please include the correct value or values and a source where we can verify.


Cancel


Submit






Your requested update has been submitted
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.


Close


























   Kimberly Manhard | Heron Therapeutics, Inc. | ZoomInfo.com








Kimberly J. Manhard - Executive Bio, Compensation History, and Contacts - Equilar Atlas










 

















Log in | Sign up








x

 






As Featured In



















Kimberly J. Manhard
Executive Vice President, Drug Development at Heron Therapeutics, Inc.


View Full Profile
Are you Kimberly J. Manhard? Claim your profile


 


Sign up for Equilar Atlas and view Kimberly J. Manhard's full profile. 
With Equilar Atlas, you can:



IDENTIFY corporate executives in Kimberly J. Manhard's  network and community.
												FOLLOW changes in Kimberly J. Manhard's employment and money-in-motion.
												CONNECT with Kimberly J. Manhard through your network of contacts.
												








Kimberly J. Manhard's Executive Work History


Current


Executive Vice President, Drug Development, 
Heron Therapeutics, Inc.


Past
To view Kimberly J. Manhard's complete executive work history, sign up now
Age
57

 
 


Kimberly J. Manhard's Biography



Kimberly J. Manhard joined us as Executive Vice President, Drug Development in January 2016. Ms. Manhard served as a director of Heron from January 2014 until she joined the management team. Ms. Manhard has more than 25 years of experience in drug development, regulatory affairs and pharmaceutical operations. From May 2008 to January 2016, Ms. Manhard served as the Senior Vice President of Regulatory Affairs and Development Operations at Ardea Biosciences, Inc., a wholly-owned subsidiary of AstraZeneca PLC. In her role at Ardea, Ms. Manhard was instrumental in the development and December 2015 regulatory approval of Zurampic� (lesinurad) for  ...
(Read More)

			Kimberly J. Manhard joined us as Executive Vice President, Drug Development in January 2016. Ms. Manhard served as a director of Heron from January 2014 until she joined the management team. Ms. Manhard has more than 25 years of experience in drug development, regulatory affairs and pharmaceutical operations. From May 2008 to January 2016, Ms. Manhard served as the Senior Vice President of Regulatory Affairs and Development Operations at Ardea Biosciences, Inc., a wholly-owned subsidiary of AstraZeneca PLC. In her role at Ardea, Ms. Manhard was instrumental in the development and December 2015 regulatory approval of Zurampic� (lesinurad) for the treatment of hyperuricemia associated with gout. Prior to joining Ardea in 2006, Ms. Manhard was President of her own consultancy firm, Vice President of Regulatory Affairs for Exelixis, Inc. and held multiple regulatory positions at Agouron Pharmaceuticals, Inc., a division of the Warner-Lambert Company, supporting development and commercialization of anticancer and antiviral products, including Viracept� (nelfinavir). She was also previously with Bristol-Myers Squibb Company in regulatory affairs, responsible for oncology compounds, including Taxol� (paclitaxel) and infectious disease compounds, including Videx� (didanosine) and Zerit� (stavudine). Ms. Manhard began her industry career in clinical research with Eli Lilly and Company and G.H. Besselaar Associates (Covance, Inc.). Ms. Manhard received a B.S. degree in zoology and a B.A. degree in French from the University of Florida.
		
Source: Heron Therapeutics, Inc. on 04/26/2017
		
	

 






Sign up for Equilar Atlas and view Kimberly J. Manhard's full profile. 



												By accessing Equilar Atlas, you can view bios, network, salary and wealth events
												of industry-leading executives like Kimberly J. Manhard. More specifically, you'll be able to:
												

IDENTIFY corporate executives in Kimberly J. Manhard's  network and community.
												FOLLOW changes in Kimberly J. Manhard's employment and money-in-motion.
												CONNECT with Kimberly J. Manhard through your network of conections.
												




View Full Profile


 








Search for over 360,000 executive profiles.





/bio



													Example: Kimberly J. Manhard


















Kimberly J. Manhard's Connections (30)





Sign up now to view Kimberly J. Manhard's 30 connections »









Henry J. Fuchs
President, Worldwide Research and Development, BioMarin Pharmaceutical Inc.









David T. Hagerty
Executive Vice President, Clinical Development, Conatus Pharmaceuticals Inc.









Julian C. Baker
Board Member, Genomic Health, Inc.









Stephen R. Davis
Dir., President and Chief Executive Officer, ACADIA Pharmaceuticals Inc.









Brian G. Drazba
Former Vice President, Finance and Chief Financial Officer, Heron Therapeutics, Inc.









Wendy L. Dixon
Board Member, Incyte Corporation









Barry D. Quart
Dir., Chief Executive Officer, Principal Financial Officer and Principal Accounting Officer, Heron Therapeutics, Inc.









Craig A. Johnson
Board Member, La Jolla Pharmaceutical Company









Paul G. Marshall
Former Senior Vice President, Technical Operations, Heron Therapeutics, Inc.









John B. Whelan
Former President, Chief Executive Officer and Chief Financial Officer, Heron Therapeutics, Inc.








Popular Profiles






														Sign up now to view more executive profiles »
														









John J. Kita
EVP and CFO, A. O. Smith









Elon R. Musk
CEO and Chairman, Tesla









Thomas J. Lynch
Executive Chairman, TE Connectivity Ltd.









Jan Koum
Board Member, Facebook, Inc.









Robert D. Perlmutter
Senior EVP and COO, The Macerich Company












×

Claim Your Profile Coming Soon
Interested in updating your biography and work history?
We're working on making it happen.
We'll email you when this feature is available.
Please enter valid email address.

Done


Thank you for your interest.
Ok






			Browse executive profiles:
			
				 A
			
				 B
			
				 C
			
				 D
			
				 E
			
				 F
			
				 G
			
				 H
			
				 I
			
				 J
			
				 K
			
				 L
			
				 M
			
				 N
			
				 O
			
				 P
			
				 Q
			
				 R
			
				 S
			
				 T
			
				 U
			
				 V
			
				 W
			
				 X
			
				 Y
			
				 Z



Equilar Homepage
Equilar Atlas
Equilar Insight
Equilar BoardEdge
Equilar Engage
Research Services
Knowledge Network
About Us
Login

� 2017 Equilar All Rights Reserved. Privacy Policy
1100 Marshall Street, Redwood City, CA 94063 | Phone (650) 241-6600 | Fax (650) 701-0993
















403 - Forbidden: Access is denied.



Server Error


403 - Forbidden: Access is denied.
You do not have permission to view this directory or page using the credentials that you supplied.







HRTX Kimberly J. Manhard Insider Trades for Heron Therapeutics Inc.


































Bulletin






Investor Alert







London Markets Close in:



Currencies
Futures
Metals Stocks


















Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close































Heron Therapeutics Inc.

                  NASDAQ: HRTX
          



GO



Set Alerts
Find a Broker




Join TD Ameritrade




Market Index


 

Overview
      
Profile
      
News
      
Charts
      
Financials
      
Historical Quotes
      
Analyst Estimates
      
Options
      
SEC Filings
      
Insiders
      


/marketstate/country/us

Heron Therapeutics Inc.



Market open
 --Real time quotes
Jul 21, 2017, 11:04 a.m.


HRTX

/quotes/zigman/28133492/composite


$
16.70




Change

-0.80
-4.57%

Volume
Volume 189,229
Real time quotes








/quotes/zigman/28133492/composite
Previous close

$
			17.50
		


$
				16.70
			
Change

-0.80
-4.57%





Day low
Day high
$16.65
$17.58










52 week low
52 week high

            $12.21
        

            $24.00
        


















Insider Activity


Individual




Kimberly J. Manhard



Ms. Kimberly J. Manhard is Director & Executive VP-Drug Development at Heron Therapeutics, Inc. and Director & Corporate Compliance Officer at Ardea Biosciences, Inc. She is on the Board of Directors at Heron Therapeutics, Inc. and Ardea Biosciences, Inc. 
Ms. Manhard was previously employed as Head-Regulatory Affairs by Agouron Global Commercial Operations, Head-Regulatory Affairs by Bristol-Myers Squibb Co., a Principal by Eli Lilly & Co., Vice President-Regulatory Affairs by Exelixis, Inc., and a Principal by G.H. Besselaar Associates. 
She received her undergraduate degree from the University of Florida.



Transactions


Date
Shares
Transaction
Value





04/24/2017
21,542


 
Disposition at $15.33 per share.


330,239


04/24/2017
16,292


 
Derivative/Non-derivative trans. at $9.05 per share.


147,442


04/24/2017
5,250


 
Derivative/Non-derivative trans. at $8.8 per share.


46,200


06/02/2015
10,500


 
Disposition at $23.58 per share.


247,590


06/02/2015
10,500


 
Derivative/Non-derivative trans. at $8.8 per share.


92,400


06/01/2015
2,708


 
Disposition at $21.17 per share.


57,329


06/01/2015
2,708


 
Derivative/Non-derivative trans. at $9.05 per share.


24,507





        Copyright 2017 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
    











            Officers and Executives
        





Mr. Kevin C. Tang 
Chairman




Mr. Robert H. Rosen 
President, Director & Chief Commercial Officer




Dr. Barry D. Quart 
Chief Executive Officer & Director




Mr. Robert E. Hoffman 
Chief Financial Officer & Senior VP-Finance




Dr. Thomas B. Ottoboni 
SVP-Pharmaceutical, Research & Development




Ms. Kimberly J. Manhard 
Executive Vice President-Drug Development




Mr. Christian  Waage 
Director




Mr. Daniel  Martin 
Vice President-Marketing




Mr. David L. Szekeres 
Secretary, Senior VP, General Counsel & IR Contact




Mr. Sean T. Ristine 
Vice President-Human Resources




Mr. John W. Poyhonen 
Independent Director




Mr. Craig A. Johnson 
Independent Director









Trending Tickers


/quotes/zigman/17636479/composite VUZI+15.60%


/quotes/zigman/237947/composite JCP-5.83%


/quotes/zigman/59392505/composite NUGT-2.93%


/quotes/zigman/59386294/composite JNUG-5.94%


/quotes/zigman/65801738/composite TLT+1.11%


X




Powered by














Log In




11:05 AM EDT
July 21, 2017


/marketstate/country/us
New York

	Open


/marketstate/country/uk
London

	Open


/marketstate/country/jp
Tokyo

	Closed





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
11:00aO.J. Simpson made over $400,000 while in prison and won’t have to give any of it to the Goldman family
10:59aCostco price target cut to $180 from $190 at Cowen & Co.
10:58aGE stock price target cut to $27 from $36 at CFRA
10:58aCiti goes neutral on Tesla stock, but counts itself in bull camp
10:58aGE downgraded to hold from buy at CFRA
10:54aTour de France: Do You Know What Day It Is?
10:40aGermany's DAX 30 drops 1.9% as part of selloff in European stocks 
10:34aThese 7 highly taxed companies need Congress to finally act on tax reform
10:34aCalifornia wildfire raging near Yosemite National Park displaces at least 5,000 residents
10:31aChristopher Nolan’s ‘Dunkirk’: 'Virtual Reality Without the Headset'
10:25aHere’s something that can improve your memory — and help you sleep
10:25aStill not losing weight? These may be the reasons why
10:22aMastercard welcomes UK court ruling to block $18 billion class action suit
10:21aSam Adams’ new 12-pack offers up its dream team
10:15aU.S. stocks fall from near-records, with GE a particular drag
10:13aDow's early tumble is broad based and led by Goldman, GE and Caterpillar stocks
10:12aSeven years after Dodd-Frank passage, there still aren’t proposals for a fifth of rules
10:00aEuro sits at 2-year high as hawkish view on  ECB dominates
9:59aMicrosoft rides huge tax benefit from failing at smartphones to big earnings beat 
9:59aAmazon effect blamed for spike in default rate among riskier retailers 
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,525.17

-86.61
-0.40%





nasdaq

/quotes/zigman/12633936/realtime
6,368.51

-21.49
-0.34%





s&p 500

/quotes/zigman/3870025/realtime
2,466.35

-7.10
-0.29%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15























































需要安全验证




Facebook加入或登录 Facebook   邮箱或手机号密码忘记帐户？登录想加入 Facebook 吗？注册注册安全验证码请输入以下文本看不清楚上面的文字？换一个或播放语音验证信息框中文字：这是什么？安全验证这是一个标准的安全测试，用于阻止垃圾邮件制造者创建假帐户并向用户发送垃圾信息。提交中文(简体)English (US)日本語한국어Français (France)Bahasa IndonesiaPolskiEspañolPortuguês (Brasil)DeutschItalianoMessengerFacebook Lite用户地点游戏位置名人二手市场小组食谱彩色气球Instagram公司简介创建广告创建主页开发者招聘信息隐私权政策Cookie广告选项条款设置活动日志 Facebook © 2017





Microsoft personalized ad preferences




 













To opt out of personalized ads in this browser, your browser history must allow first-party and third-party cookies and you must have your browsing experience set to NOT delete browsing history on exit. Instructions for enabling cookies and configuring your browsing history may be available in your browsers settings, privacy, or help documentation.

















Sign in
















  Hold on… We’re sorry but this didn’t work.                  You can’t turn off personalized ads right now because your browser is currently blocking third-party cookies. We can help you fix this issue.                Let’s get started:  Depending on what browser you use, open Options or Settings.                  Make sure that third-party cookies are not blocked anymore. To find out how, search your browser’s Help.                                 Revisit http://choice.microsoft.com/opt-out, and then on the “Personalized ads in this browser” tile, click Off.                 ext74081 




  About Our Ads To create a more customized online experience, some of the ads you may receive on Microsoft websites and apps are tailored to your previous activities, searches and site visits. You're in control and here's where you can make the advertising choice that's right for you. ext74075 




  Where Can I Learn More about Advertising on Microsoft Websites and Apps? Microsoft partners with Oath, AppNexus and other third party service providers to help present customized content and display advertisements on MSN, Outlook.com and other websites and apps. Microsoft also delivers search ads to Bing and our search syndication partners. Learn more about Microsoft’s privacy practices here. You can learn more about interest-based ads from Oath and AppNexus in their privacy statements: Oath and AppNexus. What Choices Do I Have About Interest-Based Advertising? On this page, you can opt out of receiving interest based advertising from Microsoft. You can also opt out of receiving interest-based advertising from all self-regulatory members, including Microsoft, Oath, AppNexus and other third party ad networks, at the following sites:  In the US: Digital Advertising Alliance (DAA) In Europe: European Interactive Digital Advertising Alliance (EDAA) In Canada: Ad Choices: Digital Advertising Alliance of Canada (DAAC)  You can control interest-based advertising in Windows apps by turning off the advertising ID in Windows Settings.  More choices  Do you want personalized ads from other companies?  Questions? If you have a privacy question or a question for the Chief Privacy Officer of Microsoft, please contact us by using our web form. We will respond to questions within 30 days. ext74076 




       Personalized ads in this browser     OFF    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting for this web browser.  Learn more           If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.          ext74078 




       Personalized ads wherever I use my Microsoft account     OFF   Sign in to change...    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting that applies when you are signed in on any computer or device with your Microsoft account, including Windows, Windows phone, Xbox and other devices.  Learn more                    If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.         If you choose “generic” ads and use a browser, your choice applies to everyone when using that browser as long as you do not clear your cookies.          ext74079 




       Personalized ads in Windows         In your Windows Settings, you can turn off personalized ads that appear in apps on this device. You’ll still see ads, but they won’t be personalized anymore.     If you have Windows 8.1:            Access the charms by touching or moving your pointer to the right edge of the screen.                 Click or tap Settings, and then click or tap Change PC Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have Windows 10:            Click or tap the Start button.                 Click or tap Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have a Windows mobile device:            Go to Settings.                 Tap on Privacy.                 Tap on Advertising ID, and then turn off Let apps use my advertising ID for experiences across apps.                If you want to turn off personalized ads from Microsoft wherever you use your Microsoft account including apps on Windows, Windows Phone, Xbox and other devices, you can do so by selecting the Microsoft account option above.    ext74080 














Legal
Privacy & Cookies
© 2017 Microsoft




















Amazon.com: manhard: Books







 


























Interesting Finds Updated Daily










Amazon




    Try Prime
  


















Books



All Departments
Alexa Skills
Amazon Devices
Amazon Video
Amazon Warehouse Deals
Appliances
Apps & Games
Arts, Crafts & Sewing
Automotive Parts & Accessories
Baby
Beauty & Personal Care
Books
CDs & Vinyl
Cell Phones & Accessories
Clothing, Shoes & Jewelry
   Women
   Men
   Girls
   Boys
   Baby
Collectibles & Fine Art
Computers
Courses
Credit and Payment Cards
Digital Music
Electronics
Gift Cards
Grocery & Gourmet Food
Handmade
Health, Household & Baby Care
Home & Business Services
Home & Kitchen
Industrial & Scientific
Kindle Store
Luggage & Travel Gear
Luxury Beauty
Magazine Subscriptions
Movies & TV
Musical Instruments
Office Products
Patio, Lawn & Garden
Pet Supplies
Prime Exclusive
Prime Pantry
Software
Sports & Outdoors
Tools & Home Improvement
Toys & Games
Vehicles
Video Games
Wine





Go

















Departments









EN

 
      




Hello. Sign inAccount & ListsSign inAccount & ListsOrdersTry PrimeCart0






Your Amazon.comToday's DealsGift Cards & RegistrySellHelpDisability Customer Support 






Books Advanced Search New Releases NEW! Amazon Charts Best Sellers & More The New York Times® Best Sellers Children's Books Textbooks Textbook Rentals Sell Us Your Books Best Books of the Month Kindle eBooks 




















































































1-12 of 40 results for Books : 
"manhard"


"manhard" 
                                





                                 Cancel









Sort by 
Relevance
Featured
Price: Low to High
Price: High to Low
Avg. Customer Review
Publication Date
Most reviews

























Did you mean: man hard



Goof ProoferDec 31, 1999by Stephen ManhardMass Market Paperback
$
5
79

$9.99PrimeGet it by Tomorrow, Jul 22FREE Shipping on eligible ordersMore Buying Choices$1.29(66 used &amp new offers)Paperback$14.99(2 used &amp new offers)
4.5 out of 5 stars
19The Goof-Proofer1987by Stephen J. ManhardPaperback$1.99(43 used &amp new offers)
4.7 out of 5 stars
2Manhard: Personalisiertes Notizbuch, DIN A5, 80 blanko Seiten mit kleiner Katze auf jeder rechten unteren Seite. Durch Vornamen auf dem Cover, eine ... Über 2500 Namen bereits verf (German Edition)Oct 12, 2016by edition cumulusPaperback
$
6
99

PrimeGet it by Tomorrow, Jul 22FREE Shipping on eligible ordersThe Goof-Proofer How to Avoid the 41 Most Embarrassing Errors in Your Speaking and Writing - 1998 publication.Jan 15, 2000by Stephen ManhardMass Market Paperback$3.67(36 used &amp new offers)









Manhard: individualisiertes Malbuch / Notizbuch / Tagebuch - Zebra - A4 - blanko (German Edition)May 22, 2016by personalisiertes MalbuchPaperback
$
4
99

PrimeGet it by Tomorrow, Jul 22FREE Shipping on eligible ordersGoof Proofer by Manhard, Stephen published by Touchstone (1999)1994by aaPaperback$3.74(37 used &amp new offers)Brother slave (A manhard book)1978by Sebastian LambUnknown Binding$17.29(1 used &amp new offers)Lifeguard for lunch (A manhard book)1974by George WilsonUnknown Binding$19.45(2 used &amp new offers)Put it in! (MANHARD books)1973by Jock MartinUnknown Binding$15.85(2 used &amp new offers)2017: personalisierter Kalender 2017 "Manhard" - DIN A5 - eine Woche pro Doppelseite (German Edition)May 22, 2016by individualisierter KalenderPaperback
$
6
99

PrimeGet it by Tomorrow, Jul 22FREE Shipping on eligible ordersBy Stephen Manhard Goof ProoferJan 15, 2000Mass Market Paperback$46.36(8 used &amp new offers)By Stephen J. Manhard The Goof-Proofer (English Language) [Paperback]Dec 17, 1986Paperback$24.10(9 used &amp new offers)












 
Previous Page
1
2
3
4
 
Next Page
















Sponsored Links
(What's this?)








Ad feedback











Search FeedbackDid you find what you were looking for?YesNo
Choose a category that best describes the issue that you are having with the search:Choose a category…I need to talk to customer service.I still haven't found what I'm looking for.How do I filter or sort my search ?Something is broken.A picture or description looks wrong.Could you add a feature ?Could you start carrying a product not listed here ?Choose a category…







Leave us some comments about your search; your comments can help make our site better for everyone.Submit

Get Express customer service or contact us by e-mail or phone.contact us

Thank you for your feedback.
If you need help or have a question for Customer Service, please visit the Help Section.









Show results for
                                Any CategoryBooksSchools & TeachingReferenceWriting Skill ReferenceGrammar ReferenceArts & PhotographyEducation & TeachingGay & LesbianLiterature & FictionPolitics & Social SciencesSee moreRefine byDelivery DayGet It by TomorrowAmazon PrimeEligible for Free ShippingFree Shipping by AmazonEducation Subject MatterLanguage Arts & ReadingBook FormatPaperbackKindle EditionAuthorStephen Johnson ManhardAvg. Customer Review4 Stars & Up & Up3 Stars & Up & Up2 Stars & Up & Up1 Star & Up & UpInternational ShippingAmazonGlobal EligibleConditionCollectibleNewUsedAvailabilityInclude Out of Stock





































































There's a problem loading this menu right now.
Learn more about Amazon Prime.






 Get fast, free shipping with Amazon Prime 
 Prime members enjoy FREE Two-Day Shipping and exclusive access to music, movies, TV shows, original audio series, and Kindle books. 

      >
      Get started















































        Your recently viewed items and featured recommendations
    



 › 
View or edit your browsing history

After viewing product detail pages, look here to find an easy way to navigate back to pages you are interested in.






        Your recently viewed items and featured recommendations
    



 › 
View or edit your browsing history

After viewing product detail pages, look here to find an easy way to navigate back to pages you are interested in.








Back to top
Get to Know UsCareersAbout AmazonInvestor RelationsAmazon DevicesMake Money with UsSell on AmazonSell Your Services on AmazonSell on Amazon BusinessSell Your Apps on AmazonBecome an AffiliateAdvertise Your ProductsSelf-Publish with UsBecome an Amazon VendorSell Your Subscription on Amazon›See allAmazon Payment ProductsAmazon Rewards Visa Signature CardsAmazon.com Store CardAmazon.com Corporate Credit LineShop with PointsCredit Card MarketplaceReload Your BalanceAmazon Currency ConverterLet Us Help YouYour AccountYour OrdersShipping Rates & PoliciesAmazon PrimeReturns & ReplacementsManage Your Content and DevicesAmazon AssistantHelp




English



United States




Amazon Music Stream millions of songs

Amazon Drive Cloud storage from Amazon

6pm Score deals on fashion brands

AbeBooks Books, art & collectibles

ACX  Audiobook Publishing Made Easy

Alexa Actionable Analytics for the Web

Amazon Business Everything For Your Business

 

AmazonFresh Groceries & More Right To Your Door

AmazonGlobal Ship Orders Internationally

Home Services Handpicked Pros Happiness Guarantee

Amazon Inspire Digital Educational  Resources

Amazon Rapids Fun stories for  kids on the go

Amazon Restaurants Food delivery from local restaurants

Amazon Video Direct Video Distribution Made Easy

 

Amazon Web Services Scalable Cloud Computing Services

Audible Download Audio Books

AudiobookStand Discount Audiobooks on Disc

Book Depository Books With Free Delivery Worldwide

Box Office Mojo Find Movie Box Office Data

ComiXology Thousands of Digital Comics

CreateSpace Indie Print Publishing Made Easy

 

DPReview Digital Photography

East Dane Designer Men's Fashion

Fabric Sewing, Quilting & Knitting

Goodreads Book reviews & recommendations

IMDb Movies, TV & Celebrities

IMDbPro Get Info Entertainment Professionals Need

Junglee.com Shop Online in India

 

Kindle Direct Publishing Indie Digital Publishing Made Easy


Prime Now FREE 2-Hour Delivery on Everyday Items

Prime Photos Unlimited Photo Storage Free With Prime

Shopbop Designer Fashion Brands

TenMarks.com Math Activities for Kids & Schools

Warehouse Deals Open-Box Discounts

Whispercast Discover & Distribute Digital Content


 

 

Withoutabox Submit to Film Festivals

Woot! Deals and  Shenanigans

Zappos Shoes & Clothing

Souq.com Shop Online in the Middle East

Subscribe with Amazon Discover & try subscription services

 


Conditions of UsePrivacy NoticeInterest-Based Ads© 1996-2017, Amazon.com, Inc. or its affiliates































Amazon Prime

































Interesting Finds Updated Daily










Amazon




    Try Prime
  


















All



All Departments
Alexa Skills
Amazon Devices
Amazon Video
Amazon Warehouse Deals
Appliances
Apps & Games
Arts, Crafts & Sewing
Automotive Parts & Accessories
Baby
Beauty & Personal Care
Books
CDs & Vinyl
Cell Phones & Accessories
Clothing, Shoes & Jewelry
   Women
   Men
   Girls
   Boys
   Baby
Collectibles & Fine Art
Computers
Courses
Credit and Payment Cards
Digital Music
Electronics
Gift Cards
Grocery & Gourmet Food
Handmade
Health, Household & Baby Care
Home & Business Services
Home & Kitchen
Industrial & Scientific
Kindle Store
Luggage & Travel Gear
Luxury Beauty
Magazine Subscriptions
Movies & TV
Musical Instruments
Office Products
Patio, Lawn & Garden
Pet Supplies
Prime Exclusive
Prime Pantry
Software
Sports & Outdoors
Tools & Home Improvement
Toys & Games
Vehicles
Video Games
Wine





Go

















Departments









EN

 
      




Hello. Sign inAccount & ListsSign inAccount & ListsOrdersTry PrimeCart0






Your Amazon.comToday's DealsGift Cards & RegistrySellHelpDisability Customer Support 
















































































There's a problem loading this menu right now.
Learn more about Amazon Prime.






 Get fast, free shipping with Amazon Prime 
 Prime members enjoy FREE Two-Day Shipping and exclusive access to music, movies, TV shows, original audio series, and Kindle books. 

      >
      Get started






























 



Fast, FREE shipping and morePrime members also enjoy exclusive access to movies and TV shows, ad-free music, Kindle books, original audio series and unlimited photo storage.








Start your 30-day Prime free trial 

After your free trial, Amazon Prime is just $10.99/month.  Cancel anytime.
                    
                              See more plans  ›


Give the gift of Prime | 
                            Refer a friend | 
                            Have a Prime promo code?




    
    
    



Fast, FREE shipping on over 50 million eligible itemsChoose from FREE Two-Hour, Same-Day or Two-Day Delivery with Prime    
    
    



Need a last minute gift? Can’t get out of the house? Realize you forgot to pick up something? With FREE Two-Day Shipping and more from Amazon Prime, your shopping problems are solved. You get unlimited deliveries with no minimum order size, and with millions of eligible items, the options are practically limitless. When shipping to select metro areas, Prime members also get FREE Same-Day Delivery on over a million items and FREE 2-hour delivery with Prime Now on daily essentials and groceries. With FREE release-date delivery on eligible pre-order items, you can enjoy highly anticipated books, movies, and video games as soon as possible. 
Learn more about all the Prime shipping options

    
    
    



Enjoy instant access to video streaming    
    
    



Prime includes popular movies and TV shows    
    
    



Make every night a movie night with Prime Video. Your Prime membership includes instant access to thousands of movies and TV shows at no additional cost. Catch Amazon Original Series like Golden Globe-winning Transparent, Mozart in the Jungle, and Goliath, Emmy-winning Man in the High Castle, or exciting and wildly popular The Grand Tour. Stream on select Smart TVs, Roku, Xbox, Amazon Fire TV, iPhones, tablets, and Android devices. Download entertainment to your device to watch offline anywhere.
Browse movies and TV shows
    
    
    



Over two million songs. Thousands of playlists and stations.    
    
    



On-demand, ad-free music streaming     
    
    



Prime Music is a music streaming benefit featuring a growing selection of two million songs, Alexa voice-integration, and personalized recommendations at no additional cost with your Amazon Prime Membership. Unlock even more music with Amazon Music Unlimited, plus get an exclusive Prime member discount.
Learn more
    
    
    



Books, Magazines & More    
    
    



Unlimited reading on any device    
    
    



Prime Reading gives you unlimited access to over a thousand books, current issue magazines, books with Audible narration, comics, Kindle Singles, and more. With access from any device – including your phone, tablet, or Kindle – you can read however you want, whenever you want.
Learn more
    
    
    



Original audio series from Audible    
    
    



Unlimited listening to original audio series    
    
    



Get hooked on original audio series from Audible: hunt for clues with intrepid investigators, think big with bold visionaries, or ‘keep it real’ with fearless comedians. Listen to insightful and engaging playlists handcrafted for every interest and refreshed daily, drawing from news, comedy shows, articles, talks and more. Whether you want to turn rush hour into an adventure with a great story or master a new topic while riding the train, your commute will never be the same. Audible Channels–from Audible, a world leader in audio entertainment.
Learn More
    
    
    



Twitch Prime    
    
    



Get free game content every month, exclusive discounts, plus loads more    
    
    



Get a member exclusive discount on new release and preorder boxed video games. You'll get characters, vehicles, skins, and boosts for top games on Twitch, plus surprises like full indie games and exclusive loot. You also receive ad-free viewing and a free monthly Twitch channel subscription to support your favorite streamer.
Learn more
    
    
    



All your photos, together at last    
    
    



Free unlimited photo storage    
    
    



Your Prime membership comes with free unlimited photo storage through Prime Photos, which lets you securely save as many photos as you like and see them on your phone, computer, or tablet. You can share this Prime benefit and give free photo storage to up to five family members or friends. Collect photos together with your invited family and friends in the Family Vault and store memories from everyone in one safe place. New photo search technology makes it easy to find specific photos by searching for things like “sunset” or “Seattle,” and your photos are organized automatically so it’s easy to find and enjoy them.
Learn more
    
    
    



Prime Rewards    
    
    



Cardmembers earn 5% Back with a Prime Credit Card.    
    
    



Eligible Prime members can earn 5% back at Amazon.com using the Amazon Prime Rewards Visa Card or the Amazon Prime Store card. All Prime members earn 2% rewards on their debit spending with Amazon Prime Reload.
Learn More

    
    
    



Get Early Access    
    
    



30-minute early access to select Amazon Lightning Deals    
    
    



Consider yourself a techy, the best-styled fashionista on the block, or just an everyday savvy shopper? Be among the first to decide what's hot and what's not. Get 30-minute early access to select Lightning Deals on Amazon.

Shop Amazon Lightning Deals

Look for Prime eligible items, videos, music and Kindle books are clearly marked. Just look for the Prime logo when you shop. 














  Back to top      Get to Know Us   Careers   About Amazon   Investor Relations   Amazon Devices      Make Money with Us   Sell on Amazon   Sell Your Services on Amazon   Sell on Amazon Business   Sell Your Apps on Amazon   Become an Affiliate   Advertise Your Products   Self-Publish with Us   Become an Amazon Vendor   Sell Your Subscription on Amazon   › See all      Amazon Payment Products   Amazon Rewards Visa Signature Cards   Amazon.com Store Card   Amazon.com Corporate Credit Line   Shop with Points   Credit Card Marketplace   Reload Your Balance   Amazon Currency Converter      Let Us Help You   Your Account   Your Orders   Shipping Rates & Policies   Amazon Prime   Returns & Replacements   Manage Your Content and Devices   Amazon Assistant   Help                   English   United States          Amazon Music Stream millionsof songs       Amazon Drive Cloud storagefrom Amazon       6pm Score dealson fashion brands       AbeBooks Books, art& collectibles       ACX Audiobook PublishingMade Easy       Alexa Actionable Analyticsfor the Web       Amazon Business Everything ForYour Business          AmazonFresh Groceries & MoreRight To Your Door       AmazonGlobal Ship OrdersInternationally       Home Services Handpicked ProsHappiness Guarantee       Amazon Inspire Digital EducationalResources       Amazon Rapids Fun stories forkids on the go       Amazon Restaurants Food delivery fromlocal restaurants       Amazon Video Direct Video DistributionMade Easy          Amazon Web Services Scalable CloudComputing Services       Audible DownloadAudio Books       AudiobookStand Discount Audiobookson Disc       Book Depository Books With FreeDelivery Worldwide       Box Office Mojo Find MovieBox Office Data       ComiXology Thousands ofDigital Comics       CreateSpace Indie Print PublishingMade Easy          DPReview DigitalPhotography       East Dane Designer Men'sFashion       Fabric Sewing, Quilting& Knitting       Goodreads Book reviews& recommendations       IMDb Movies, TV& Celebrities       IMDbPro Get Info EntertainmentProfessionals Need       Junglee.com Shop Onlinein India          Kindle Direct Publishing Indie Digital PublishingMade Easy       Prime Now FREE 2-Hour Deliveryon Everyday Items       Prime Photos Unlimited Photo StorageFree With Prime       Shopbop DesignerFashion Brands       TenMarks.com Math Activitiesfor Kids & Schools       Warehouse Deals Open-BoxDiscounts       Whispercast Discover & DistributeDigital Content               Withoutabox Submit toFilm Festivals       Woot! Deals andShenanigans       Zappos Shoes &Clothing       Souq.com Shop Online inthe Middle East       Subscribe with Amazon Discover & trysubscription services               Conditions of Use   Privacy Notice   Interest-Based Ads   © 1996-2017, Amazon.com, Inc. or its affiliates    










v



































Amazon.com: Amazon Music Unlimited








































Interesting Finds Updated Daily










Amazon




    Try Prime
  


















Digital Music



All Departments
Alexa Skills
Amazon Devices
Amazon Video
Amazon Warehouse Deals
Appliances
Apps & Games
Arts, Crafts & Sewing
Automotive Parts & Accessories
Baby
Beauty & Personal Care
Books
CDs & Vinyl
Cell Phones & Accessories
Clothing, Shoes & Jewelry
   Women
   Men
   Girls
   Boys
   Baby
Collectibles & Fine Art
Computers
Courses
Credit and Payment Cards
Digital Music
Electronics
Gift Cards
Grocery & Gourmet Food
Handmade
Health, Household & Baby Care
Home & Business Services
Home & Kitchen
Industrial & Scientific
Kindle Store
Luggage & Travel Gear
Luxury Beauty
Magazine Subscriptions
Movies & TV
Musical Instruments
Office Products
Patio, Lawn & Garden
Pet Supplies
Prime Exclusive
Prime Pantry
Software
Sports & Outdoors
Tools & Home Improvement
Toys & Games
Vehicles
Video Games
Wine





Go

















Departments









EN

 
      




Hello. Sign inAccount & ListsSign inAccount & ListsOrdersTry PrimeCart0






Your Amazon.comToday's DealsGift Cards & RegistrySellHelpDisability Customer Support 






 Amazon Music Unlimited Prime Music CDs & Vinyl Download Store         Open Web Player MP3 cart Settings








































































































$7.99/mo for Prime members




Non-Prime price: $9.99/month



Change or cancel anytime




            Start your 30-day free trial
          




$7.99/mo for Prime members




Non-Prime price: $9.99/month



Change or cancel anytime




            Start your 30-day free trial
          




$7.99/mo for Prime members




Non-Prime price: $9.99/month



Change or cancel anytime




            Start your 30-day free trial
          
















Any song, anywhere




Tens of millions of songs with new releases from today's most popular artists. Listen ad-free with unlimited skips. Download for offline listening.




Any song, anywhere




Tens of millions of songs with new releases from today's most popular artists. Listen ad-free with unlimited skips. Download for offline listening.




Any song, anywhere




Tens of millions of songs with new releases from today's most popular artists. Listen ad-free with unlimited skips. Download for offline listening.
















Already using Prime Music?




Upgrade to Amazon Music Unlimited now to unlock tens of millions of songs, including the hottest new releases. Only $7.99/month or $79/year (12 months for the price of 10).




Already using Prime Music?




Upgrade to Amazon Music Unlimited now to unlock tens of millions of songs, including the hottest new releases. Only $7.99/month or $79/year (12 months for the price of 10).




Already using Prime Music?




Upgrade to Amazon Music Unlimited now to unlock tens of millions of songs, including the hottest new releases. Only $7.99/month or $79/year (12 months for the price of 10).
















Better with Echo - Just ask




Play your favorite music with innovative Alexa voice controls, exclusive to Amazon Music.




Want Amazon Music Unlimited just on your Echo? Learn More




Better with Echo - Just ask




Play your favorite music with innovative Alexa voice controls, exclusive to Amazon Music.




Want Amazon Music Unlimited just on your Echo? Learn More




Better with Echo - Just ask




Play your favorite music with innovative Alexa voice controls, exclusive to Amazon Music.




Want Amazon Music Unlimited just on your Echo? Learn More


























Choose the right Amazon Music plan for you




Learn More




Learn More




Learn More




Questions? See our FAQ.





            Start free trial
          




Choose the right Amazon Music plan for you




Learn More




Learn More




Learn More




Questions? See our FAQ.





            Start free trial
          




Choose the right Amazon Music plan for you




Learn More




Learn More




Learn More




Questions? See our FAQ.





            Start free trial
          

















There's a problem loading this menu right now.
Learn more about Amazon Prime.






 Get fast, free shipping with Amazon Prime 
 Prime members enjoy FREE Two-Day Shipping and exclusive access to music, movies, TV shows, original audio series, and Kindle books. 

      >
      Get started

















v























